Vivek Agrawal CFA
Stock Analyst at Citi
(0.43)
# 4,386
Out of 4,712 analysts
21
Total ratings
44.4%
Success rate
-12.8%
Average return
Main Sectors:
Stocks Rated by Vivek Agrawal CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: CIPLA Cipla Limited | Maintained: Buy | n/a | $1,375.20 | - | 2 | Jul 24, 2026 | |
| NSE: SUNPHARMA Sun Pharmaceutical Industries Limited | Maintained: Buy | ₹2,180 | ₹1,878 | +16.10% | 2 | Sep 30, 2025 | |
| NSE: MAXHEALTH Max Healthcare Institute Limited | Maintained: Buy | ₹1,460 | ₹1,032 | n/a | 1 | Aug 11, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Maintained: Sell | ₹1,100 → ₹1,010 | ₹1,685 | n/a | 3 | Aug 6, 2025 | |
| NSE: LAURUSLABS Laurus Labs Limited | Maintained: Sell | ₹500.00 → ₹590.00 | ₹1,942 | n/a | 2 | Jul 28, 2025 | |
| NSE: GLAND Gland Pharma Limited | Maintained: Sell | ₹1,680 | ₹2,957 | n/a | 1 | Jul 22, 2025 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Maintained: Buy | ₹8,260 | ₹8,925 | n/a | 1 | Jun 30, 2025 | |
| NSE: DRREDDY Dr. Reddy's Laboratories Limited | Maintained: Sell | ₹990.00 | ₹1,143 | n/a | 1 | Jun 27, 2025 | |
| NSE: DIVISLAB Divi's Laboratories Limited | Maintained: Buy | ₹7,050 → ₹7,750 | ₹9,511 | n/a | 2 | May 19, 2025 | |
| NSE: LALPATHLAB Dr. Lal PathLabs Limited | Maintained: Sell | ₹1,350 | ₹1,923 | n/a | 1 | Apr 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ₹700.00 | ₹754.20 | n/a | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | ₹2,260 | ₹2,100 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ₹2,330 → ₹1,880 | ₹1,461 | n/a | 2 | Feb 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | ₹430.00 | ₹397.85 | n/a | 1 | Feb 3, 2025 |
Cipla Limited
Jul 24, 2026
Maintained: Buy
Price Target: n/a
Current: $1,375.20
Upside: -
Sun Pharmaceutical Industries Limited
Sep 30, 2025
Maintained: Buy
Price Target: ₹2,180
Current: ₹1,878
Upside: +16.10%
Max Healthcare Institute Limited
Aug 11, 2025
Maintained: Buy
Price Target: ₹1,460
Current: ₹1,032
Upside: n/a
Aurobindo Pharma Limited
Aug 6, 2025
Maintained: Sell
Price Target: ₹1,100 → ₹1,010
Current: ₹1,685
Upside: n/a
Laurus Labs Limited
Jul 28, 2025
Maintained: Sell
Price Target: ₹500.00 → ₹590.00
Current: ₹1,942
Upside: n/a
Gland Pharma Limited
Jul 22, 2025
Maintained: Sell
Price Target: ₹1,680
Current: ₹2,957
Upside: n/a
Apollo Hospitals Enterprise Limited
Jun 30, 2025
Maintained: Buy
Price Target: ₹8,260
Current: ₹8,925
Upside: n/a
Dr. Reddy's Laboratories Limited
Jun 27, 2025
Maintained: Sell
Price Target: ₹990.00
Current: ₹1,143
Upside: n/a
Divi's Laboratories Limited
May 19, 2025
Maintained: Buy
Price Target: ₹7,050 → ₹7,750
Current: ₹9,511
Upside: n/a
Dr. Lal PathLabs Limited
Apr 27, 2025
Maintained: Sell
Price Target: ₹1,350
Current: ₹1,923
Upside: n/a
Mar 12, 2025
Initiated Coverage: Buy
Price Target: ₹700.00
Current: ₹754.20
Upside: n/a
Mar 5, 2025
Upgraded: Buy
Price Target: ₹2,260
Current: ₹2,100
Upside: n/a
Feb 16, 2025
Maintained: Hold
Price Target: ₹2,330 → ₹1,880
Current: ₹1,461
Upside: n/a
Feb 3, 2025
Maintained: Buy
Price Target: ₹430.00
Current: ₹397.85
Upside: n/a